Intech Biopharm（6461）株式概要インテック・バイオファーム・コーポレーションは、台湾内外で呼吸器疾患治療薬のジェネリック医薬品の開発・製造を行っている。 詳細6461 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間6.8%減少しました。 意味のある収益がありません ( NT$117M )意味のある時価総額がありません ( NT$3B )すべてのリスクチェックを見る6461 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW479,582 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA479,582 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$15.90286.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-433m482m2016201920222025202620282031Revenue NT$482.3mEarnings NT$70.2mAdvancedSet Fair ValueView all narrativesIntech Biopharm Corporation 競合他社Easywell BiomedicalsSymbol: TPEX:1799Market cap: NT$4.1bSunWay BiotechSymbol: TPEX:1271Market cap: NT$3.7bTSH BiopharmSymbol: TPEX:8432Market cap: NT$1.9bSYN-TECH Chem. & PharmSymbol: TPEX:1777Market cap: NT$3.3b価格と性能株価の高値、安値、推移の概要Intech Biopharm過去の株価現在の株価NT$15.9052週高値NT$26.2552週安値NT$14.10ベータ0.151ヶ月の変化4.61%3ヶ月変化-14.52%1年変化-16.97%3年間の変化-47.78%5年間の変化-25.87%IPOからの変化-82.13%最新ニュースReported Earnings • May 16First quarter 2026 earnings released: NT$0.63 loss per share (vs NT$0.64 loss in 1Q 2025)First quarter 2026 results: NT$0.63 loss per share. Net loss: NT$111.9m (loss widened 27% from 1Q 2025).Reported Earnings • Mar 27Full year 2025 earnings released: NT$2.57 loss per share (vs NT$2.68 loss in FY 2024)Full year 2025 results: NT$2.57 loss per share. Net loss: NT$389.0m (loss widened 5.7% from FY 2024).New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.18b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Market cap is less than US$100m (NT$3.18b market cap, or US$99.2m).お知らせ • Mar 06Intech Biopharm Corporation, Annual General Meeting, May 27, 2026Intech Biopharm Corporation, Annual General Meeting, May 27, 2026. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city TaiwanNew Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m).Reported Earnings • Nov 12Third quarter 2025 earnings released: NT$0.88 loss per share (vs NT$0.70 loss in 3Q 2024)Third quarter 2025 results: NT$0.88 loss per share (further deteriorated from NT$0.70 loss in 3Q 2024). Net loss: NT$144.1m (loss widened 50% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesReported Earnings • May 16First quarter 2026 earnings released: NT$0.63 loss per share (vs NT$0.64 loss in 1Q 2025)First quarter 2026 results: NT$0.63 loss per share. Net loss: NT$111.9m (loss widened 27% from 1Q 2025).Reported Earnings • Mar 27Full year 2025 earnings released: NT$2.57 loss per share (vs NT$2.68 loss in FY 2024)Full year 2025 results: NT$2.57 loss per share. Net loss: NT$389.0m (loss widened 5.7% from FY 2024).New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.18b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Market cap is less than US$100m (NT$3.18b market cap, or US$99.2m).お知らせ • Mar 06Intech Biopharm Corporation, Annual General Meeting, May 27, 2026Intech Biopharm Corporation, Annual General Meeting, May 27, 2026. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city TaiwanNew Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m).Reported Earnings • Nov 12Third quarter 2025 earnings released: NT$0.88 loss per share (vs NT$0.70 loss in 3Q 2024)Third quarter 2025 results: NT$0.88 loss per share (further deteriorated from NT$0.70 loss in 3Q 2024). Net loss: NT$144.1m (loss widened 50% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.New Risk • Nov 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$371m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$371m free cash flow). Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.7m). Market cap is less than US$100m (NT$2.51b market cap, or US$80.8m).New Risk • Sep 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.93b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.8m). Market cap is less than US$100m (NT$2.93b market cap, or US$96.6m).Reported Earnings • Aug 11Second quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.68 loss in 2Q 2024)Second quarter 2025 results: NT$0.23 loss per share (improved from NT$0.68 loss in 2Q 2024). Net loss: NT$33.2m (loss narrowed 64% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m).New Risk • Jun 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m).Reported Earnings • May 14First quarter 2025 earnings released: NT$0.64 loss per share (vs NT$0.55 loss in 1Q 2024)First quarter 2025 results: NT$0.64 loss per share (further deteriorated from NT$0.55 loss in 1Q 2024). Net loss: NT$88.4m (loss widened 18% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.お知らせ • Apr 29Intech Biopharm Corporation to Report Q1, 2025 Results on May 06, 2025Intech Biopharm Corporation announced that they will report Q1, 2025 results on May 06, 2025Reported Earnings • Mar 18Full year 2024 earnings released: NT$2.68 loss per share (vs NT$2.81 loss in FY 2023)Full year 2024 results: NT$2.68 loss per share. Net loss: NT$368.2m (loss widened 8.9% from FY 2023).New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.30b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$34m revenue, or US$1.0m). Market cap is less than US$100m (NT$3.30b market cap, or US$100.0m).お知らせ • Mar 06+ 1 more updateIntech Biopharm Corporation, Annual General Meeting, May 20, 2025Intech Biopharm Corporation, Annual General Meeting, May 20, 2025, at 09:00 Taipei Standard Time. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwanお知らせ • Feb 25Intech Biopharm Corporation to Report Fiscal Year 2024 Results on Mar 04, 2025Intech Biopharm Corporation announced that they will report fiscal year 2024 results on Mar 04, 2025Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$0.70 loss per share (vs NT$0.73 loss in 3Q 2023)Third quarter 2024 results: NT$0.70 loss per share. Net loss: NT$96.0m (loss widened 12% from 3Q 2023).New Risk • Oct 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: NT$32m (US$999k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.2% per year over the past 5 years. Revenue is less than US$1m (NT$32m revenue, or US$999k). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.68 loss per share (vs NT$0.62 loss in 2Q 2023)Second quarter 2024 results: NT$0.68 loss per share (further deteriorated from NT$0.62 loss in 2Q 2023). Net loss: NT$92.6m (loss widened 27% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 02Intech Biopharm Corporation to Report Q2, 2024 Results on Aug 09, 2024Intech Biopharm Corporation announced that they will report Q2, 2024 results on Aug 09, 2024お知らせ • Apr 28Intech Biopharm Corporation to Report Q1, 2024 Results on May 03, 2024Intech Biopharm Corporation announced that they will report Q1, 2024 results on May 03, 2024Reported Earnings • Mar 15Full year 2023 earnings released: NT$2.81 loss per share (vs NT$2.82 loss in FY 2022)Full year 2023 results: NT$2.81 loss per share. Net loss: NT$338.0m (loss widened 3.1% from FY 2022).お知らせ • Mar 02Intech Biopharm Corporation, Annual General Meeting, May 24, 2024Intech Biopharm Corporation, Annual General Meeting, May 24, 2024. Location: 1F., No.207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City 114, Taiwan(Xue Xue Institute) Taipei City Taiwan Agenda: To report Business Report of 2023; to report Audit Committees Review Report of 2023; to report the implementation of the 2023 Business Plan; to acknowledge adoption of the 2023 Business Report and Financial Statements; to acknowledge adoption of the proposal for 2023 Deficit Compensation Statement; to discuss and approve the lifting of non-competition restrictions for directors of the Company; and to consider other matters.New Risk • Dec 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.4% per year over the past 5 years. Revenue is less than US$1m (NT$25m revenue, or US$787k). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).New Risk • Oct 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.8% per year over the past 5 years. Revenue is less than US$1m (NT$20m revenue, or US$630k). Minor Risk Market cap is less than US$100m (NT$3.20b market cap, or US$99.2m).Reported Earnings • Aug 11Second quarter 2023 earnings released: NT$0.62 loss per share (vs NT$0.73 loss in 2Q 2022)Second quarter 2023 results: NT$0.62 loss per share (improved from NT$0.73 loss in 2Q 2022). Net loss: NT$72.8m (loss narrowed 14% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Mar 31Full year 2022 earnings released: NT$2.82 loss per share (vs NT$2.97 loss in FY 2021)Full year 2022 results: NT$2.82 loss per share. Net loss: NT$327.9m (loss widened 8.7% from FY 2021).Reported Earnings • Nov 16Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021)Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021).Reported Earnings • Nov 13Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021)Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021).Reported Earnings • Aug 15Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.82 loss in 2Q 2021)Second quarter 2022 results: NT$0.73 loss per share. Net loss: NT$84.4m (loss widened 2.6% from 2Q 2021).Reported Earnings • May 16First quarter 2022 earnings released: NT$0.60 loss per share (vs NT$0.68 loss in 1Q 2021)First quarter 2022 results: NT$0.60 loss per share. Net loss: NT$69.2m (loss widened 1.9% from 1Q 2021).Reported Earnings • Mar 30Full year 2021 earnings released: NT$2.97 loss per share (vs NT$2.50 loss in FY 2020)Full year 2021 results: NT$2.97 loss per share (down from NT$2.50 loss in FY 2020). Net loss: NT$301.8m (loss widened 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$0.71 loss per share (vs NT$0.65 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$71.7m (loss widened 9.4% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.82 loss per share (vs NT$0.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$82.3m (loss widened 38% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Reported Earnings • May 17First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.60 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$67.9m (loss widened 13% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: NT$2.50 loss per share (vs NT$3.82 loss in FY 2019)Full year 2020 results: Net loss: NT$250.4m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.分析記事 • Mar 24Is Intech Biopharm (GTSM:6461) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...お知らせ • Mar 11Intech Biopharm Corporation, Annual General Meeting, May 28, 2021Intech Biopharm Corporation, Annual General Meeting, May 28, 2021.分析記事 • Dec 09Intech Biopharm (GTSM:6461) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Dec 03New 90-day high: NT$23.10The company is up 13% from its price of NT$20.40 on 04 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.65 loss per shareThird quarter 2020 results: Net loss: NT$65.6m (loss narrowed 19% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 26New 90-day low: NT$20.05The company is down 1.0% from its price of NT$20.20 on 28 July 2020. The Taiwanese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.株主還元6461TW PharmaceuticalsTW 市場7D2.3%-3.2%-2.0%1Y-17.0%-13.5%90.3%株主還元を見る業界別リターン: 6461過去 1 年間で-13.5 % の収益を上げたTW Pharmaceuticals業界を下回りました。リターン対市場: 6461は、過去 1 年間で90.3 % のリターンを上げたTW市場を下回りました。価格変動Is 6461's price volatile compared to industry and market?6461 volatility6461 Average Weekly Movement4.5%Pharmaceuticals Industry Average Movement4.8%Market Average Movement6.5%10% most volatile stocks in TW Market12.0%10% least volatile stocks in TW Market2.7%安定した株価: 6461 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6461の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201096Manish Chawlawww.intechbiopharm.comIntech Biopharm Corporationは、台湾および海外で呼吸器疾患治療薬のジェネリック医薬品の開発・製造を行っている。同社は、喘息およびCOPD治療用の定量吸入器プラットフォームであるiLEF（吸入低エタノール製剤）、およびブリスターとカプセルからなるドライパウダー吸入器を所有している。同社は、SYN006、SYN010、SYN007、Synflutide、Duasma、Synvent、SYN011の製品名で製品を提供している。Intech Biopharm Corporationは2010年に設立され、台湾の台北に本社を置いている。もっと見るIntech Biopharm Corporation 基礎のまとめIntech Biopharm の収益と売上を時価総額と比較するとどうか。6461 基礎統計学時価総額NT$2.84b収益（TTM）-NT$412.53m売上高(TTM)NT$117.49m24.1xP/Sレシオ-6.9xPER（株価収益率6461 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6461 損益計算書（TTM）収益NT$117.49m売上原価NT$230.21m売上総利益-NT$112.72mその他の費用NT$299.81m収益-NT$412.53m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.31グロス・マージン-95.94%純利益率-351.13%有利子負債／自己資本比率127.8%6461 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 18:47終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Intech Biopharm Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 16First quarter 2026 earnings released: NT$0.63 loss per share (vs NT$0.64 loss in 1Q 2025)First quarter 2026 results: NT$0.63 loss per share. Net loss: NT$111.9m (loss widened 27% from 1Q 2025).
Reported Earnings • Mar 27Full year 2025 earnings released: NT$2.57 loss per share (vs NT$2.68 loss in FY 2024)Full year 2025 results: NT$2.57 loss per share. Net loss: NT$389.0m (loss widened 5.7% from FY 2024).
New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.18b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Market cap is less than US$100m (NT$3.18b market cap, or US$99.2m).
お知らせ • Mar 06Intech Biopharm Corporation, Annual General Meeting, May 27, 2026Intech Biopharm Corporation, Annual General Meeting, May 27, 2026. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m).
Reported Earnings • Nov 12Third quarter 2025 earnings released: NT$0.88 loss per share (vs NT$0.70 loss in 3Q 2024)Third quarter 2025 results: NT$0.88 loss per share (further deteriorated from NT$0.70 loss in 3Q 2024). Net loss: NT$144.1m (loss widened 50% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • May 16First quarter 2026 earnings released: NT$0.63 loss per share (vs NT$0.64 loss in 1Q 2025)First quarter 2026 results: NT$0.63 loss per share. Net loss: NT$111.9m (loss widened 27% from 1Q 2025).
Reported Earnings • Mar 27Full year 2025 earnings released: NT$2.57 loss per share (vs NT$2.68 loss in FY 2024)Full year 2025 results: NT$2.57 loss per share. Net loss: NT$389.0m (loss widened 5.7% from FY 2024).
New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.18b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m). Market cap is less than US$100m (NT$3.18b market cap, or US$99.2m).
お知らせ • Mar 06Intech Biopharm Corporation, Annual General Meeting, May 27, 2026Intech Biopharm Corporation, Annual General Meeting, May 27, 2026. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$418m free cash flow). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$114m revenue, or US$3.6m).
Reported Earnings • Nov 12Third quarter 2025 earnings released: NT$0.88 loss per share (vs NT$0.70 loss in 3Q 2024)Third quarter 2025 results: NT$0.88 loss per share (further deteriorated from NT$0.70 loss in 3Q 2024). Net loss: NT$144.1m (loss widened 50% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
New Risk • Nov 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$371m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$371m free cash flow). Earnings have declined by 7.0% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.7m). Market cap is less than US$100m (NT$2.51b market cap, or US$80.8m).
New Risk • Sep 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$2.93b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$115m revenue, or US$3.8m). Market cap is less than US$100m (NT$2.93b market cap, or US$96.6m).
Reported Earnings • Aug 11Second quarter 2025 earnings released: NT$0.23 loss per share (vs NT$0.68 loss in 2Q 2024)Second quarter 2025 results: NT$0.23 loss per share (improved from NT$0.68 loss in 2Q 2024). Net loss: NT$33.2m (loss narrowed 64% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
New Risk • Jun 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m).
New Risk • Jun 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$372m free cash flow). Earnings have declined by 6.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (NT$33m revenue, or US$1.1m).
Reported Earnings • May 14First quarter 2025 earnings released: NT$0.64 loss per share (vs NT$0.55 loss in 1Q 2024)First quarter 2025 results: NT$0.64 loss per share (further deteriorated from NT$0.55 loss in 1Q 2024). Net loss: NT$88.4m (loss widened 18% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • Apr 29Intech Biopharm Corporation to Report Q1, 2025 Results on May 06, 2025Intech Biopharm Corporation announced that they will report Q1, 2025 results on May 06, 2025
Reported Earnings • Mar 18Full year 2024 earnings released: NT$2.68 loss per share (vs NT$2.81 loss in FY 2023)Full year 2024 results: NT$2.68 loss per share. Net loss: NT$368.2m (loss widened 8.9% from FY 2023).
New Risk • Mar 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.30b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.2% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$34m revenue, or US$1.0m). Market cap is less than US$100m (NT$3.30b market cap, or US$100.0m).
お知らせ • Mar 06+ 1 more updateIntech Biopharm Corporation, Annual General Meeting, May 20, 2025Intech Biopharm Corporation, Annual General Meeting, May 20, 2025, at 09:00 Taipei Standard Time. Location: 4 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan
お知らせ • Feb 25Intech Biopharm Corporation to Report Fiscal Year 2024 Results on Mar 04, 2025Intech Biopharm Corporation announced that they will report fiscal year 2024 results on Mar 04, 2025
Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$0.70 loss per share (vs NT$0.73 loss in 3Q 2023)Third quarter 2024 results: NT$0.70 loss per share. Net loss: NT$96.0m (loss widened 12% from 3Q 2023).
New Risk • Oct 05New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: NT$32m (US$999k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.2% per year over the past 5 years. Revenue is less than US$1m (NT$32m revenue, or US$999k). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.68 loss per share (vs NT$0.62 loss in 2Q 2023)Second quarter 2024 results: NT$0.68 loss per share (further deteriorated from NT$0.62 loss in 2Q 2023). Net loss: NT$92.6m (loss widened 27% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 02Intech Biopharm Corporation to Report Q2, 2024 Results on Aug 09, 2024Intech Biopharm Corporation announced that they will report Q2, 2024 results on Aug 09, 2024
お知らせ • Apr 28Intech Biopharm Corporation to Report Q1, 2024 Results on May 03, 2024Intech Biopharm Corporation announced that they will report Q1, 2024 results on May 03, 2024
Reported Earnings • Mar 15Full year 2023 earnings released: NT$2.81 loss per share (vs NT$2.82 loss in FY 2022)Full year 2023 results: NT$2.81 loss per share. Net loss: NT$338.0m (loss widened 3.1% from FY 2022).
お知らせ • Mar 02Intech Biopharm Corporation, Annual General Meeting, May 24, 2024Intech Biopharm Corporation, Annual General Meeting, May 24, 2024. Location: 1F., No.207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City 114, Taiwan(Xue Xue Institute) Taipei City Taiwan Agenda: To report Business Report of 2023; to report Audit Committees Review Report of 2023; to report the implementation of the 2023 Business Plan; to acknowledge adoption of the 2023 Business Report and Financial Statements; to acknowledge adoption of the proposal for 2023 Deficit Compensation Statement; to discuss and approve the lifting of non-competition restrictions for directors of the Company; and to consider other matters.
New Risk • Dec 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 6.4% per year over the past 5 years. Revenue is less than US$1m (NT$25m revenue, or US$787k). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
New Risk • Oct 06New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.20b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.8% per year over the past 5 years. Revenue is less than US$1m (NT$20m revenue, or US$630k). Minor Risk Market cap is less than US$100m (NT$3.20b market cap, or US$99.2m).
Reported Earnings • Aug 11Second quarter 2023 earnings released: NT$0.62 loss per share (vs NT$0.73 loss in 2Q 2022)Second quarter 2023 results: NT$0.62 loss per share (improved from NT$0.73 loss in 2Q 2022). Net loss: NT$72.8m (loss narrowed 14% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 31Full year 2022 earnings released: NT$2.82 loss per share (vs NT$2.97 loss in FY 2021)Full year 2022 results: NT$2.82 loss per share. Net loss: NT$327.9m (loss widened 8.7% from FY 2021).
Reported Earnings • Nov 16Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021)Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021).
Reported Earnings • Nov 13Third quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.71 loss in 3Q 2021)Third quarter 2022 results: NT$0.65 loss per share. Net loss: NT$75.1m (loss widened 4.7% from 3Q 2021).
Reported Earnings • Aug 15Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.82 loss in 2Q 2021)Second quarter 2022 results: NT$0.73 loss per share. Net loss: NT$84.4m (loss widened 2.6% from 2Q 2021).
Reported Earnings • May 16First quarter 2022 earnings released: NT$0.60 loss per share (vs NT$0.68 loss in 1Q 2021)First quarter 2022 results: NT$0.60 loss per share. Net loss: NT$69.2m (loss widened 1.9% from 1Q 2021).
Reported Earnings • Mar 30Full year 2021 earnings released: NT$2.97 loss per share (vs NT$2.50 loss in FY 2020)Full year 2021 results: NT$2.97 loss per share (down from NT$2.50 loss in FY 2020). Net loss: NT$301.8m (loss widened 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Third quarter 2021 earnings released: NT$0.71 loss per share (vs NT$0.65 loss in 3Q 2020)Third quarter 2021 results: Net loss: NT$71.7m (loss widened 9.4% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Aug 18Second quarter 2021 earnings released: NT$0.82 loss per share (vs NT$0.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: NT$82.3m (loss widened 38% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Reported Earnings • May 17First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.60 loss in 1Q 2020)First quarter 2021 results: Net loss: NT$67.9m (loss widened 13% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: NT$2.50 loss per share (vs NT$3.82 loss in FY 2019)Full year 2020 results: Net loss: NT$250.4m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
分析記事 • Mar 24Is Intech Biopharm (GTSM:6461) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
お知らせ • Mar 11Intech Biopharm Corporation, Annual General Meeting, May 28, 2021Intech Biopharm Corporation, Annual General Meeting, May 28, 2021.
分析記事 • Dec 09Intech Biopharm (GTSM:6461) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Dec 03New 90-day high: NT$23.10The company is up 13% from its price of NT$20.40 on 04 September 2020. The Taiwanese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
Reported Earnings • Nov 14Third quarter 2020 earnings released: NT$0.65 loss per shareThird quarter 2020 results: Net loss: NT$65.6m (loss narrowed 19% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 26New 90-day low: NT$20.05The company is down 1.0% from its price of NT$20.20 on 28 July 2020. The Taiwanese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period.
